MEDIAN Technologies will present results of a study on September 29 from 9:30 to 12:00 in Hall 4: “Monitoring of Pulmonary Tumors in Computed Tomography: Thresholds for Volume-based Response Assessments and Target Lesions Selection”.
MEDIAN Technologies coauthored a poster publication presented by Saga University, Japan: “Evaluation of a Cloud-based Local Read Paradigm for Imaging Evaluations in Oncology Clinical Trials” scheduled September, 29 9:30 to 12:00 in Hall 4.
The MEDIAN Technologies team will be available at Booth 3567 to discuss study results and to give demonstrations of MEDIAN’s software solutions.
MEDIAN Technologies (ALMDT), a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials, today announced its participation in the European Cancer Congress (ECC), to be held next Sept. 27-Oct. 1, in Amsterdam, The Netherlands.
During the ECC — the premier European oncology conference, co-organized this year by the European Cancer Organization (ECCO), the European Society for Medical Oncology (ESMO) and the European Society for Radiotherapy and Oncology (ESTRO) — MEDIAN’s scientists will present the results of a study “Monitoring of Pulmonary Tumors in Computed Tomography: Thresholds for Volume-based Response Assessments and Target Lesions Selection” scheduled September, 29 9:30 to 12:00 in Hall 4 –http://eccamsterdam2013.ecco-org.eu/Scientific-Programme/Abstract-search.aspx (Abstract number 1150). Changes in lung tumor volume are emerging as a more sensitive imaging biomarker for disease evolution than uni-dimensional measurements of longest axial diameters. However, there are still missing scientific data to specify the magnitude of tumor volume changes that would allow classifying disease evolution and identifying if a patient responded to the therapy. This study proposes a solution for volume-based response assessments that provides thresholds for response, based on tumor volume, as well as a method for automatic identification of measurable lesions.
MEDIAN Technologies has also coauthored a poster publication presented by Saga University, Japan: “Evaluation of a Cloud-based Local Read Paradigm for Imaging Evaluations in Oncology Clinical Trials” scheduled September, 29th 9:30 to 12:00 in Hall 4 – http://eccamsterdam2013.ecco-org.eu/Scientific-Programme/Abstract-search.aspx (Abstract number 1153). The goal of the study is to evaluate a cloud-based paradigm implementing software solutions and services that standardize imaging evaluations among international investigator sites. The study was performed using MEDIAN’s Lesion Management Solutions (LMS) and MEDIAN’s Clinical Trial Imaging Services (CTIS).
MEDIAN’s scientific and business development teams will be present at Booth 3567 to discuss study results and to give demonstrations of MEDIAN’s LMS solutions.